€40 Million Long COVID Fund Dries Up—While a Cure Still Feels Out of Reach
It’s the kind of headline that stirs both frustration and fear: the €40 million research fund dedicated to long COVID is nearly gone. And just as patients hoped the money might bring them closer to recovery, scientists warn that progress could grind to a halt. According to a recent NOS survey involving doctors, researchers, patient groups, and funding bodies, the financial well has almost run dry. Researchers can still apply for the final round of grants before the year ends—but don’t expect a breakthrough anytime soon. The harsh truth? A cure for long COVID remains an elusive goal.
Across the Netherlands, nearly half a million people continue to battle long COVID symptoms. These range from chronic fatigue and muscle pain to brain fog and breathing difficulties. Many can’t return to work, can’t exercise, and struggle to sleep properly. For about 100,000 of them, life has been reduced to varying degrees of confinement—some rarely leaving bed.
Experts are sounding the alarm. Without additional funding, much of the valuable expertise built over the last few years could simply vanish. “The result would naturally be a loss of expertise and knowledge,” said Niels Eijkelkamp, professor of neuro-immunology at UMC Utrecht. “It would mean wasting millions in public investments and leaving promising research trails unexplored in our quest to understand long COVID.” And this is where the debate heats up—should governments double down on funding for long COVID, or spread limited research money more evenly across other pressing diseases?
Right after the pandemic broke out, politicians rushed to show support for long COVID patients. Fast forward five years, and that attention has waned dramatically, NOS reports. Yet the crisis didn’t end with the pandemic—it only evolved. Thousands remain seriously ill, trapped in a cycle of uncertainty and fatigue. Their frustration is mirrored in communities with similar post-viral conditions, such as ME/CFS, Q-fever fatigue syndrome, Lyme disease, and post-sepsis syndrome.
The human cost of these illnesses is staggering. Stella Heemskerk, a researcher at Erasmus MC, conducted a four-year study involving 644 people affected by Q-fever fatigue syndrome. Her findings were sobering: half of those who worked before falling ill never returned to their jobs, and nearly three-quarters suffered significant financial losses. Families often stepped in as caregivers, sacrificing time, careers, and stability in the process.
So where does that leave long COVID patients now—abandoned by funding cycles and political interest? Should governments be held accountable for letting crucial medical research lose momentum, especially when so many lives still hang in the balance? Share your thoughts: is this a funding failure, or an unavoidable shift in post-pandemic priorities?
